phthalidyl 6,7-dichloro-5-N,N-dimethylsulfamoyl-2,3-dihydrobenzofuran-2-carboxylate | 103969-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: phthalidyl 6,7-dichloro-5-N,N-dimethylsulfamoyl-2,3-dihydrobenzofuran-2-carboxylate
• 英文别名: 1-phthalidyl 5-(N,N-dimethylsulfamoyl)-6,7-dichloro-2,3-dihydrobenzofuran-2-carboxylate；(3-oxo-1H-2-benzofuran-1-yl) 6,7-dichloro-5-(dimethylsulfamoyl)-2,3-dihydro-1-benzofuran-2-carboxylate
• CAS: 103969-14-8
• 化学式: C₁₉H₁₅Cl₂NO₇S
• 分子量: 472.303
• InChiKey: KUHSJNHZPRPAHN-UHFFFAOYSA-N

物化性质

• 沸点：
  653.7±65.0 °C(Predicted)
• 密度：
  1?+-.0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  108
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  6,7-dichloro-5-N,N-dimethylsulfamoyl-2,3-dihydrobenzofuran-2-carboxylic acid 在 potassium carbonate 作用下， 以 N-甲基乙酰胺 、 乙腈 为溶剂， 以56%的产率得到phthalidyl 6,7-dichloro-5-N,N-dimethylsulfamoyl-2,3-dihydrobenzofuran-2-carboxylate
  参考文献：
  名称：

  2,3-dihydrobenzofuran-5-sulfonamide derivatives useful as

  摘要：

  高效利尿降压药，即2,3-二氢苯并呋喃-5-磺酰胺衍生物，属于被归类为循环利尿剂的药物，具有较少的不良副作用，可口服每日剂量为0.5-200毫克，或者静脉注射每日剂量为0.01-50毫克。

  公开号：

  US04659709A1

文献信息

• Studies on uricosuric diuretics. I. 6,7-Dichloro-5-sulfamoyl-2,3-dihydrobenzofuran-2-carboxylic acids.
  作者：HIROSHI HARADA、YOSHIHIRO MATSUSHITA、MITSUAKI YODO、MASUHISA NAKAMURA、YUKIO YONETANI

  DOI：10.1248/cpb.35.3195

  日期：——

  2, 3-Dihydrobenzofuran derivatives having various sulfamoyl groups at the 5-position were synthesized and tested for oral diuretic and saluretic activities in rats and mice. Intraperitoneal uricosuric activity was also tested by a clearance method using oxonate-treated rats. Structureactivity relationships are presented. The 6, 7-dichloro-5-N, N-disubstituted sulfamoyl-2, 3-dihydro-benzofuran-2-carboxylic acids (9ab, ac, 13a and b) having lower alkyl substituents showed the most potent diuretic and saluretic activities among the compounds synthesized. Hyperuricosuric activity was observed in 6, 7-dichloro-2, 3-dihydrobenzofuran-2-carboxylic acids and 2-hydroxymethyl-6, 7-dichloro-2, 3-dihydrobenzofurans having a 5-sulfamoyl group, with relatively small substituents (9aa-ac, af, ak, al, an, ao and 16a-c). The saluretic activity of 9ab showed a high-ceiling profile. Examination of the enantiomers of 9ab revealed that the (-) -enantiomer is responsible for most of the diuretic and saluretic activities, while the (+) -enantiomer is responsible for most of the uricosuric activity.

  5-位含有各种磺酰胺基团的2,3-二氢苯并呋喃衍生物被合成并在大鼠和小鼠中测试了其口服利尿和促尿钠排泄活性。还通过使用草酸盐处理的大鼠的清除法测试了腹腔内促尿酸排泄活性。介绍了构效关系。具有较低烷基取代基的6,7-二氯-5-N,N-二取代磺酰胺基-2,3-二氢苯并呋喃-2-羧酸（9ab, ac, 13a和b）在合成的化合物中显示出最强的利尿和促尿钠排泄活性。在具有5-磺酰胺基团的6,7-二氯-2,3-二氢苯并呋喃-2-羧酸和2-羟甲基-6,7-二氯-2,3-二氢苯并呋喃中观察到高尿酸盐排泄活性，取代基相对较小（9aa-ac, af, ak, al, an, ao和16a-c）。9ab的促尿钠排泄活性显示出高上限特征。检查9ab的对映体发现，（-）-对映体负责大部分利尿和促尿钠排泄活性，而（+）-对映体负责大部分促尿酸排泄活性。
• 2,3-Dihydrobenzofuran-5-sulfonamide derivatives
  申请人：SHIONOGI & CO., LTD.

  公开号：EP0173899B1

  公开（公告）日：1991-12-18
• HARADA, HIROSHI;MATSUSHITA, YOSHIHIRO;YODO, MITSUAKI;NAKAMURA, MASUHISA;Y+, CHEM. AND PHARM. BULL., 35,(1987) N 8, 3195-3214
  作者：HARADA, HIROSHI、MATSUSHITA, YOSHIHIRO、YODO, MITSUAKI、NAKAMURA, MASUHISA、Y+

  DOI：——

  日期：——
• 2,3-dihydrobenzofuran-5-sulfonamide derivatives useful as
  申请人：Shionogi & Co.

  公开号：US04659709A1

  公开（公告）日：1987-04-21

  Highly effective diuretic antihypertensives, i.e., 2,3-dihydrobenzofuran-5-sulfonamide derivatives which is classified to loop diuretics with less adverse side-effects and can be administered orally at a daily dosage of 0.5-200 mg or parenterally of 0.01-50 mg.

  高效利尿降压药，即2,3-二氢苯并呋喃-5-磺酰胺衍生物，属于被归类为循环利尿剂的药物，具有较少的不良副作用，可口服每日剂量为0.5-200毫克，或者静脉注射每日剂量为0.01-50毫克。